Bristol-Myers Squibb Company Ce (CELG-RI) Stock Price & Analysis
Bristol-Myers Squibb Company Ce (CELG-RI) — price $0.14 (-12.45%), as of the Nov 19, 2026 trading session; market cap $142B.
Educational signal · not a buy or sell recommendation · How to read this
Bristol-Myers Squibb Company Ce · CELG-RI · NYSE · Healthcare · Drug Manufacturers - General
Bristol Myers Squibb Company (BMS) operates as a biopharmaceutical enterprise, managing the entire lifecycle of its therapeutic products, from initial discovery and development to manufacturing, marketing, and distribution.
Price as of Nov 19, 2026
Key Statistics
Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.
Thousands of the 20,000+ US stocks here carry a MoonshotScore.
Scored companies in the same industry:
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $0.14 | |
| Change on the day | -12.45% | |
| 52-week range | $0.10–$0.1499 | |
| Market capitalisation | $142B | |
| Price / earnings (trailing) | 13.57 | |
| Shares traded on the day | 54.9K | |
| Beta (volatility vs the S&P 500) | -0.47 |
Price & events
Other perspectives
Council score for Bristol-Myers Squibb Company Ce (CELG-RI): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
3 lenses, 3 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 19, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Nov 18, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Bristol-Myers Squibb Company Ce (CELG-RI), and what does it report?
Short answer · as of
Bristol Myers Squibb Company (BMS) operates as a biopharmaceutical enterprise, managing the entire lifecycle of its therapeutic products, from initial discovery and development to manufacturing, marketing, and distribution. Bristol-Myers Squibb Company Ce (CELG-RI) is listed on NYSE. Healthcare / Drug Manufacturers General SEC filing business address: Route 206 AND Province Line Road, Princeton, NJ, 08543. In Q2 FY2026 it reported revenue of $12.97B and net income of $3.32B. The market values it at $142B.
What do the latest results show for Bristol-Myers Squibb Company Ce (CELG-RI)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $12.97B. Against analyst estimates the company has EPS beat 8 of the last 8 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $12.97B | $3.32B | $1.62 (diluted) |
| Q1 FY2026 | $11.49B | $2.68B | $1.31 (diluted) |
| Q4 FY2025 | $12.50B | $1.09B | $0.53 (diluted) |
| Q3 FY2025 | $12.22B | $2.20B | $1.08 (diluted) |
What are the financial strengths and risks for Bristol-Myers Squibb Company Ce (CELG-RI)?
Short answer · as of
The distress and quality screens read Altman Z 1.43 · Piotroski F 7.
Data-derived red flags
- Listing risk — at $0.14 the shares sit below the $1.00 minimum bid NYSE requires for continued listing.
- Financial-distress signal — its Altman Z-Score of 1.43 sits in the distress zone (elevated bankruptcy risk).
The records behind this page
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Nov 5, 2026
- Transactions
- 43
- Identified insiders
- 14
- Purchases
- 0
- Sales
- 3
- Other transactions
- 40
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held CELG-RI in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported CELG-RI in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Bristol-Myers Squibb Company Ce (CELG-RI)?
What Investors Ask About Bristol-Myers Squibb Company Ce (CELG-RI) — Healthcare
These answers are editorial: 1 of these 8 answers is drawn from the CELG-RI research dossier (written May 9, 2026 by gpt-4o-mini); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.
Is CELG-RI a good stock to buy?
Stock Expert AI does not rate CELG-RI buy, sell or hold. Bristol-Myers Squibb Company Ce has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the CELG-RI stock price today?
The last price recorded for Bristol-Myers Squibb Company Ce (CELG-RI), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What do analysts say about CELG-RI stock?
Analysts generally view Bristol-Myers Squibb Company Ce positively, citing its strong profit margins and innovative pipeline as key strengths. Valuation metrics indicate a solid position within the industry, with growth considerations focusing on the expansion of its CAR-T therapies and ongoing research initiatives.
What are the key factors to evaluate for CELG-RI?
Evaluate CELG-RI on fundamentals, analyst consensus, and risk factors. To weigh it, start with the trailing P/E under Price & valuation on this page. Focus on CAR-T therapies positions the company at the forefront of innovative cancer treatments. Not financial advice.
How frequently does CELG-RI data refresh on this page?
CELG-RI's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven CELG-RI's recent stock price performance?
Bristol-Myers Squibb Company Ce (CELG-RI) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Strong profit and gross margins indicating operational efficiency. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CELG-RI overvalued or undervalued right now?
The trailing P/E of Bristol-Myers Squibb Company Ce (CELG-RI) is listed under Price & valuation on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of CELG-RI?
Fractional-share availability for Bristol-Myers Squibb Company Ce (CELG-RI) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.
Machine-generated analysis by Stock Expert AI — model gpt-4o-mini, generated May 9, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 19 figures on this page — 1 from SEC filings and earnings calls, 16 from Financial Modeling Prep (FMP) and 2 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com